(NASDAQ: XLO) Xilio Therapeutics's forecast annual revenue growth rate of 75.45% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.7%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.75%.
Xilio Therapeutics's revenue in 2025 is $9,274,000.On average, 1 Wall Street analysts forecast XLO's revenue for 2025 to be $3,598,867,974, with the lowest XLO revenue forecast at $3,598,867,974, and the highest XLO revenue forecast at $3,598,867,974. On average, 1 Wall Street analysts forecast XLO's revenue for 2026 to be $4,401,493,205, with the lowest XLO revenue forecast at $4,401,493,205, and the highest XLO revenue forecast at $4,401,493,205.
In 2027, XLO is forecast to generate $2,071,290,920 in revenue, with the lowest revenue forecast at $2,071,290,920 and the highest revenue forecast at $2,071,290,920.